Biopharma organizations have invested heavily in managing CMC data, yet many continue to face a less visible challenge: preserving the knowledge behind critical development decisions. As products progress through development and teams evolve, maintaining scientific context can become just as important as maintaining the underlying data.
How should BioPharma companies distinguish between moonshot automation and validated digital tools? Marc Smith shares his perspective in a Pharma’s Almanac roundtable, explaining why AI derives its value from validated ELNs, LIMS and regulated data platforms—it does not replace them.
IDBS shares results from its latest survey into the current challenges and future priorities for lab data management in the BioPharma industry.
IDBS has been awarded the Best Bioprocessing Supplier Award: Software, at the Asia Pacific Biopharma Excellence Awards (ABEA) 2025.
BioIVT has implemented the IDBS E-WorkBook platform, significantly reducing study cycle times by at least 30%.
IDBS is excited to announce the launch of Polar Control, a groundbreaking module designed to transform process management.
Could digital transformation hold the key to streamlining tech transfers, optimizing process control and reducing costly delays?
Many scientists spend time making data useable. Prioritize clean data — whether you store it on paper, in the cloud or in ancient scrolls.
IDBS, announced today that it has achieved a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.
Green practices have become everyone’s responsibility. Now, companies have intensified practices in BioPharma, whose operations have big environmental impacts.
